BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17161865)

  • 1. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference.
    Tan WB; Jiang S; Zhang Y
    Biomaterials; 2007 Mar; 28(8):1565-71. PubMed ID: 17161865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells].
    Ren SH; Wang JW; Zhang L
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(22):1530-4. PubMed ID: 16179111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted cellular uptake and siRNA silencing by quantum-dot nanoparticles coated with β-cyclodextrin coupled to amino acids.
    Zhao MX; Li JM; Du L; Tan CP; Xia Q; Mao ZW; Ji LN
    Chemistry; 2011 Apr; 17(18):5171-9. PubMed ID: 21465588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionalized silicon quantum dots tailored for targeted siRNA delivery.
    Klein S; Zolk O; Fromm MF; Schrödl F; Neuhuber W; Kryschi C
    Biochem Biophys Res Commun; 2009 Sep; 387(1):164-8. PubMed ID: 19576864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation.
    Huang Z; King MR
    Gene Ther; 2009 Oct; 16(10):1271-82. PubMed ID: 19554031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA.
    Jiang S; Zhang Y; Lim KM; Sim EK; Ye L
    Nanotechnology; 2009 Apr; 20(15):155101. PubMed ID: 19420539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted quantum dot conjugates for siRNA delivery.
    Derfus AM; Chen AA; Min DH; Ruoslahti E; Bhatia SN
    Bioconjug Chem; 2007; 18(5):1391-6. PubMed ID: 17630789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of silencing of HER2/neu gene in anti-BPDE-transformed cells.
    Jiang Y; Fu J; Greenlee AR; Shen Y; Duan H; Chen X
    Toxicol In Vitro; 2009 Feb; 23(1):53-9. PubMed ID: 18992321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
    Ren XL; Xu YM; Bao W; Fu HJ; Wu CG; Zhao Y; Li ZK; Zhang J; Li SQ; Chen WQ; Wang T; Zhang R; Zhang LH; Qian GS; Chen SY; Jia LT; Yang AG
    Cancer Lett; 2009 Aug; 281(2):134-43. PubMed ID: 19339104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intracellular delivery method for siRNA by an arginine-rich peptide.
    Wang YH; Hou YW; Lee HJ
    J Biochem Biophys Methods; 2007 Jun; 70(4):579-86. PubMed ID: 17320189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging.
    Li JM; Zhao MX; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
    Biomaterials; 2011 Nov; 32(31):7978-87. PubMed ID: 21784514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylatable short peptide conjugated low molecular weight chitosan for efficient siRNA delivery and target gene silencing.
    Kong F; Liu G; Sun B; Zhou S; Zuo A; Zhao R; Liang D
    Int J Pharm; 2012 Jan; 422(1-2):445-53. PubMed ID: 22067703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
    Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
    Dou S; Yao YD; Yang XZ; Sun TM; Mao CQ; Song EW; Wang J
    J Control Release; 2012 Aug; 161(3):875-83. PubMed ID: 22762887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
    Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
    Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
    Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
    Wang XL; Xu R; Lu ZR
    J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo.
    He XW; Liu T; Chen YX; Cheng DJ; Li XR; Xiao Y; Feng YL
    Cancer Gene Ther; 2008 Mar; 15(3):193-202. PubMed ID: 18202713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.